Anti-E2F1 antibody [EPR26698-49] - BSA and Azide free,Abcam,AB314312
ab314312 is the carrier-free version of ab314311 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Human
Application
WB
Platform ID
BAB162543764

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication (PubMed : 10675335, PubMed : 12717439, PubMed : 17050006, PubMed : 17704056, PubMed : 18625225, PubMed : 28992046). The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase (PubMed : 10675335, PubMed : 12717439, PubMed : 17704056). E2F1 binds preferentially RB1 in a cell-cycle dependent manner (PubMed : 10675335, PubMed : 12717439, PubMed : 17704056). It can mediate both cell proliferation and TP53/p53-dependent apoptosis (PubMed : 8170954). Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters (PubMed : 20176812). Directly activates transcription of PEG10 (PubMed : 17050006, PubMed : 18625225, PubMed : 28992046). Positively regulates transcription of RRP1B (PubMed : 20040599). See full target information E2F1
Category Paths
Please provide the required information below so that we can quickly source your products.
